Kidney Disease and Heart Health: Can Parathyroidectomy Help?
"Discover how parathyroidectomy (PTX) can improve heart rate variability (HRV) in chronic kidney disease patients by correcting bone markers and reducing sympathetic hyperactivity."
Cardiovascular disease (CVD) is a major health threat for individuals with chronic kidney disease (CKD). The risk of cardiovascular issues and sudden death rises significantly due to changes in the cardiac autonomic nervous system, especially overactivity of the sympathetic nervous system (SNS). This overactivity can be measured through heart rate variability (HRV), a crucial indicator of cardiac autonomic function.
Chronic kidney disease–mineral and bone disorder (CKD-MBD) is another frequent issue in CKD patients. It involves problems with mineral and bone metabolism, bone structure, and vascular calcification, all of which raise the risk of CVD and mortality. A common treatment for severe secondary hyperparathyroidism (SHPT) which contributes to bone pain, fractures, CVD, and increased mortality is parathyroidectomy (PTX).
A recent study has explored the connection between circulating bone markers and heart rate variability (HRV) in CKD patients. The findings indicate that parathyroidectomy (PTX) can enhance heart rate variability (HRV) by addressing specific bone markers and reducing sympathetic overactivity. This offers new hope for improving both kidney and heart health in this patient population.
Approaches to Parathyroidectomy
Treatment of hyperparathyroidism in chronic kidney disease includes dietary phosphate restriction, phosphate binders, correction of hypocalcemia, and other medical therapies. The NKF KDOQI Guidelines report that medical therapy is often effective, while surgical parathyroidectomy can substantially reduce serum parathyroid hormone levels. Surgical options include total parathyroidectomy without autotransplantation, total parathyroidectomy with autotransplantation, and subtotal parathyroidectomy. A 2021 review identifies subtotal parathyroidectomy as an optimal strategy in an era of increasing kidney transplantation and improved dialysis regimens, while also noting a shift toward less aggressive, patient-tailored surgery.
How Does Parathyroidectomy (PTX) Improve Heart Health in CKD Patients?
The study, published in International Urology and Nephrology, examined the effects of parathyroidectomy (PTX) on blood bone markers and heart rate variability (HRV) in patients with stage 5 chronic kidney disease. Researchers conducted a cross-sectional study involving 134 stage 5 CKD patients and 100 controls, along with a prospective study of 29 PTX patients with follow-up data.
- Intact parathyroid hormone (iPTH): Regulates bone remodeling.
- Bone-specific alkaline phosphatase (BAP): Indicates bone formation.
- Tartrate-resistant acid phosphatase 5b (TRACP-5b): Indicates bone resorption.
- Fibroblast growth factor 23 (FGF23): A bone-derived hormone.
Heart-Rate Variability After Surgery
A study of 30 patients with stage 5 chronic kidney disease and secondary hyperparathyroidism assessed outcomes a median of 6.50 months after parathyroidectomy. Improved SDNN and SDANN heart-rate-variability markers were related to decreased 1-84 PTH levels. Improved SDNN was also related to decreased 7-84 PTH levels. These findings suggest an association between postoperative PTH-fragment changes and measures of autonomic cardiac function, but the study does not establish that parathyroidectomy prevents cardiovascular events.
Persistence and Uncertain Outcomes
Evidence supporting surgical parathyroidectomy in advanced chronic kidney disease has historically been limited: the PLOS study states that, for more than six decades, surgery was performed mainly according to historical clinical practice patterns rather than evidence of outcome. A 2025 retrospective study specifically examined predictors of persistent secondary hyperparathyroidism and postoperative outcomes, indicating that persistence remains an important clinical concern. In an earlier heart-rate-variability study, patients after unsuccessful parathyroidectomy showed no significant changes in HRV. The authors cautioned that the small sample size and short follow-up created a possibility of statistical error.
Disease Burden and Baseline Measures
Surgical management is relevant because secondary hyperparathyroidism affects a majority of patients with chronic kidney disease at stage 3 or worse. In a haemodialysis study of 75 subjects, participants had a mean age of 60 ± 15 years, 32% were female, and 37% had diabetes. Their baseline PTH was 44 ± 32 pmol/l, calcium was 2.3 ± 0.2 mmol/l, and phosphate was 1.6 ± 0.4 mmol/l. These data describe the affected population and biochemical context, but they do not by themselves demonstrate that surgery is superior to nonsurgical management.
Looking Ahead: Improving the Future of CKD and Heart Health
The insights from this study offer new possibilities for managing CKD-MBD patients and reducing their cardiovascular risk. However, further research is needed to fully understand the interactions between bone markers, heart rate variability, and cardiovascular outcomes. By establishing the diagnostic and prognostic value of circulating bone biomarkers, healthcare professionals can develop more effective and integrated treatment strategies to improve the quality of life and overall health for individuals with chronic kidney disease.
What the Evidence Can Show
A PLOS meta-analysis evaluated the impact of surgical parathyroidectomy on outcomes in chronic kidney disease and end-stage kidney disease patients with secondary hyperparathyroidism. It compared patients undergoing surgery with matched patients who did not undergo surgical parathyroidectomy. This design addresses whether surgery is associated with differences in clinical outcomes, rather than relying only on biochemical changes. The source describes the analysis as an assessment of available evidence, so its conclusions should be interpreted within the limits of the underlying studies.
Timing and Surgical Strategy
A 2023 Frontiers review reports that total parathyroidectomy is indicated in 20% of patients with chronic renal failure who have been on dialysis for 3 to 10 years, and that the percentage doubles when dialysis duration reaches 20 years. For kidney transplant candidates with severe secondary hyperparathyroidism, a 2026 Frontiers article states that parathyroidectomy is widely used, while the optimal timing before versus after transplantation remains controversial. Recent discussions also continue to examine secondary hyperparathyroidism in chronic kidney disease, including bone effects, laboratory findings, treatments, and surgery. The available source material therefore points toward further research on patient selection, dialysis duration, and pre-transplant versus post-transplant timing.